SecBot SecBot
SECBOTREPLAY Home › Report › ABBV

ABBV · AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics,…

AbbVie Inc. · 8-K filed Sep 3, 2026 at 08:47 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Sep 3, 2026 at 08:47 ET

AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology assets zumilokibart (atopic dermatitis) and APG273 (asthma). AbbVie reaffirmed its FY2026 adjusted EPS guidance of $13.87-$14.07 and Q3 guidance of $3.84-$3.88, with the deal expected to dilute EPS by $0.14 in 2026 and $0.46 in 2027 before becoming accretive in 2032.

  • Acquisition of Apogee Therapeutics completed for $135.11 per share in cash, total equity value ~$10.9 billion
  • Apogee's lead asset zumilokibart (IL-13 mAb) is in Phase 2 for atopic dermatitis with potential best-in-category profile
  • Pipeline includes APG273 (IL-13 + TSLP combination) in development for asthma
  • AbbVie reaffirms FY2026 adjusted diluted EPS guidance range $13.87-$14.07

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access